Cereno Scientific AB (publ)

OM:CRNO B Stock Report

Market Cap: SEK 1.5b

Cereno Scientific Balance Sheet Health

Financial Health criteria checks 2/6

Cereno Scientific has a total shareholder equity of SEK230.7M and total debt of SEK90.4M, which brings its debt-to-equity ratio to 39.2%. Its total assets and total liabilities are SEK345.3M and SEK114.6M respectively.

Key information

39.2%

Debt to equity ratio

SEK 90.40m

Debt

Interest coverage ration/a
CashSEK 73.84m
EquitySEK 230.73m
Total liabilitiesSEK 114.55m
Total assetsSEK 345.28m

Recent financial health updates

Recent updates

Is Cereno Scientific (STO:CRNO B) Using Debt Sensibly?

Sep 26
Is Cereno Scientific (STO:CRNO B) Using Debt Sensibly?

Will Cereno Scientific (STO:CRNO B) Spend Its Cash Wisely?

Sep 01
Will Cereno Scientific (STO:CRNO B) Spend Its Cash Wisely?

We're Keeping An Eye On Cereno Scientific's (NGM:CRNO B) Cash Burn Rate

Apr 05
We're Keeping An Eye On Cereno Scientific's (NGM:CRNO B) Cash Burn Rate

Financial Position Analysis

Short Term Liabilities: CRNO B's short term assets (SEK78.5M) exceed its short term liabilities (SEK24.2M).

Long Term Liabilities: CRNO B's short term assets (SEK78.5M) do not cover its long term liabilities (SEK90.4M).


Debt to Equity History and Analysis

Debt Level: CRNO B's net debt to equity ratio (7.2%) is considered satisfactory.

Reducing Debt: CRNO B's debt to equity ratio has increased from 0.6% to 39.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CRNO B has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CRNO B has less than a year of cash runway if free cash flow continues to reduce at historical rates of 39.4% each year


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 06:32
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cereno Scientific AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jyoti PrakashEdison Investment Research
Soo RomanoffEdison Investment Research